- Home
- KZIA vs AEON Comparison
KZIA vs AEON Comparison
Compare KZIA & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- AEON
- Stock Information
- Founded
- KZIA 1994
- AEON N/A
- Country
- KZIA Australia
- AEON United States
- Employees
- KZIA N/A
- AEON N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- AEON Health Care
- Exchange
- KZIA Nasdaq
- AEON Nasdaq
- Market Cap
- KZIA 11.7M
- AEON 10.6M
- IPO Year
- KZIA 1999
- AEON N/A
- Fundamental
- Price
- KZIA $7.56
- AEON $0.89
- Analyst Decision
- KZIA Strong Buy
- AEON Strong Buy
- Analyst Count
- KZIA 3
- AEON 1
- Target Price
- KZIA $16.00
- AEON $7.20
- AVG Volume (30 Days)
- KZIA 72.8K
- AEON 258.2K
- Earning Date
- KZIA 12-26-2025
- AEON 11-12-2025
- Dividend Yield
- KZIA N/A
- AEON N/A
- EPS Growth
- KZIA N/A
- AEON N/A
- EPS
- KZIA N/A
- AEON N/A
- Revenue
- KZIA $1,246,312.00
- AEON N/A
- Revenue This Year
- KZIA N/A
- AEON N/A
- Revenue Next Year
- KZIA N/A
- AEON N/A
- P/E Ratio
- KZIA N/A
- AEON N/A
- Revenue Growth
- KZIA N/A
- AEON N/A
- 52 Week Low
- KZIA $2.86
- AEON $0.38
- 52 Week High
- KZIA $34.40
- AEON $64.80
- Technical
- Relative Strength Index (RSI)
- KZIA 54.09
- AEON 48.00
- Support Level
- KZIA $7.18
- AEON $0.89
- Resistance Level
- KZIA $7.99
- AEON $1.09
- Average True Range (ATR)
- KZIA 0.46
- AEON 0.07
- MACD
- KZIA 0.03
- AEON -0.01
- Stochastic Oscillator
- KZIA 72.19
- AEON 31.38
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.